AUTO-4 (Autolus)

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameAUTO-4 (Autolus)
Drug Alias Nameanti-T-cell receptor beta chain region C1 CAR T-cell therapyanti-TRBC1 CAR T-cell therapyAUTO-4
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > γ-retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityAnti-TRBC1
TargetsTRBC1
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAutolus Ltd
Active IndicationsN/A
Inactive IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[4] 

Other Information

ATC CodeN/A
Related LinksN/A